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ABSTRACT 
Microspheres are one of the novel drug delivery system which possess several applications and are made up of assorted polymer s. 
Microspheres can be defined as solid, approximately spherical particles ranging in size from 1 to 1000 μm range in diameter having a core of 
drug and entirely outer layers of polymers as coating material. They are made up of polymeric, waxy or other protective materials i.e. 
biodegradable synthetic polymer and modified natural products such as starches, gums, proteins, fats and wax es. Preformulation is a group of 
studies that focus on the physicochemical properties of a new drug candidate that could affect the drug performance and the development of a 
dosage form. This couldprovide important information for formulation design or support the need for molecular modification. Every drug has 
intrinsic chemical and physical properties which has been consider before development of pharmaceutical formulation. This pro perty provides 
the framework for drugs combination with pharmaceutical ingredients in the fabrication of dosage form. Objective of preformulation study is to 
develop the elegant, stable, effective and safe dosage form by establishing kinetic rate profile, compatibility with the other ingredients and 
establish Physico-chemical parameter of new drug substances. The purpose of the present study was to systematically investigate some of the 
important physicochemical properties of pralidoxime chloride for preparation of microspheres. The physicochemical properties such as 
solubility, pKa, dissolution, melting point, assay development, excipient compatibility etc. of pralidoxime chloride was carried out. Before 
selection of excipients, the Preformulation study of drug pralidoxime is completed for successful formulation of microspheres. The result of 
Preformulation studies shows good flow properties, excipient compatibility, solubility efficiency and melting point. From this study we 
concluded that pralidoximewith HPMC and EC can be used to formulate pralidoxime microspheres for modified release. 
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INTRODUCTION 
Preformulation evolved in the late 1950s and early 1960s as 
a result of a shift in emphasis in industrial pharmaceutical 
product development. It was improvement in analytical 
methods that spurred the first programs that might bear the 
name “preformulation”. The overall objective of 
preformulation testing is to generate information useful to 
the formulator in developing stable and bioavailable dosage 
forms which can be mass-produced. During the early 
development of a new drug substance, the synthetic chemist, 
alone or in co-operation with specialists in other disciplines 
including preformulation, may record some data which can 
be appropriately considered as preformulation data. Before 
starting the preformulation studies we should know the 
properties of the drug, potency relative to the competitive 
products and the dosage form, literature search providing 
stability and decay data, the proposed route of drug 
administration, literature search regarding the formulation 
approaches, bioavailability and pharmacokinetics of 
chemically related drugs. It also includes preliminary 
investigations and molecular optimization by the drug 
should be tested to determine the magnitude of each 
suspected problem area (Step I), if a deficiency is detected, a 
molecular modification should be done (Step II). To 
overcome this deficiency molecular modification is done be 
salts, prodrugs, solvates, polymorphs or even new analogues. 
The dissolution rate of a salt form of a drug is generally quite 
different from that of the parent compound. Sodium and 
potassium salts of weak organic acids and hydrochloride 
salts of weak organic bases dissolve much more readily than 
do the, respective free acids or bases. For example Ephedrine 
base is very poorly water soluble molecules that 
characterized by low solubility and dissolution rates. So, it is 
modified in the form of the salt Ephedrine HCL that is ionized 
and offer higher water solubility and dissolution rate. 
Preformulation commences when a newly synthesized drug 
shows sufficient pharmacologic promise in animal models to 
warrants evaluation in man. These studies should focus on 
those physicochemical properties of the new compound that 
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could affect drug performance and development of an 
efficacious dosage form. A thorough understanding of these 
properties may ultimately provide a rational for formulation 
design, or support the need for molecular modification1. 
Microspheres can be defined as solid, approximately 
spherical particles ranging in size from 1 to 1000μm range in 
diameter having a core of drug and entirely outer layers of 
polymers as coating material. They are made up of 
polymeric, waxy or other protective materials i.e. 
biodegradable synthetic polymer and modified natural 
products such as starches, gums, proteins, fats and waxes2.  It 
would, therefore be advantageous to have means for 
providing an intimate contact of the drug delivery system 
with the absorbing membrane. This can be achieved by 
coupling bioadhesion characteristics to microspheres3. 
Microspheres constitute an important part of such 
particulate drug delivery systems by virtue of their small size 
and efficient carrier capacity4. They have varied applications 
and are prepared by using various polymers. Mucoadhesive 
drug delivery system are delivery system which utilizes the 
property of bioadhesion of certain polymers which become 
adhesive on hydration and can be used for targeting a drug 
to a particular region of the body for extended periods of 
time. Pralidoxime chemically,2-formyl-1-methylpyridinium 
chloride oxime. It occurs as an odorless, white, 
nonhygroscopic, crystalline powder which is soluble in 
water. Stable in air, it melts between 215ºC and 225º C with 
decomposition. The specific activity of the drug resides in the 
2-formyl-1-methylpyridinium ion and is independent of the 
particular salt employed. The chloride is preferred because 
of physiologic compatibility, excellent water solubility at all 
temperatures, and high potency per gram, due to its low 
molecular weight. Pralidoxime chloride is a cholinesterase 
reactivator. Pralidoxime (PAM+, Cl-, I- and CH3SO3-) was the 
first oxime antidote for treatment of organophosphate 
(nerve gas) poisoning5-8. PAM and subsequent oximes 
(obidoxime, TMB-4, HS-6, HI-6 etc.) act through regeneration 
of the irreversibly inhibited enzyme acetylcholinesterase. 
Therapy with oximes against organophosphate poisoning 
must commence immediately after exposure since some 
organophosphates otherwise may cause permanent damage 
(ageing) to the enzyme9. Since PAM is a quarternary 
ammonium compound it is poorly and slowly absorbed from 
the gastrointestinal tract. Together with a rapid renal 
elimination the oral route will be less useful even for 
prophylaxis10-16. Intramuscular administration shows high 
availability and rapid absorption. Thus, the parenteral route 
is the best if not the only way to administer PAM to a 
poisoned individual11,13, 15.  
MATERIAL AND METHODS 
Chemicals and reagents  
Pralidoxime chloride was synthesized and taken from DRDE, 
Gwalior. All the chemicals used in this study were obtained 
from Hi Media Laboratories Pvt. Ltd. (Mumbai, India), SD 
Fine-Chem. Ltd. (Mumbai, India) and RANKEM RFCL 
Ltd.(New Delhi, India). Water was glass-double distilled and 
further purified from Milli Q water purification system. All 
the chemicals used in this study were of analytical grade. 
Methods 
The purpose of Preformulation study was to establish 
physicochemical parameters of drug, physical characteristics 
& compatibility with common excipients. Various parameters 
like melting point, solubility and drug excipients 
compatibility studies etc. were carried out. 
Solubility study 
Solubility of the drug was determined by taking some 
quantity of drug (about 1-2 mg) in the test tube separately 
and added the 5 ml of the solvent (water, ethanol, methanol, 
0.1 N HCl, 0.1 N NaOH and phosphate buffer pH 6.8). Shake 
vigorously and kept for some time. The solubility of the drug 
in various solvents was determined (at room temperature)17. 
Melting point 
It is one of the parameters to judge the purity of drugs. In 
case of pure chemicals, melting points are very sharp and 
constant. Since the drugs contain the mixed chemicals, they 
are described with certain range of melting point. The 
melting point of the drug was performed by capillary 
method. In this, drug was filled in the capillary tube sealed at 
one end to a height of 3 mm from closed end and capillary 
was introduced into melting point apparatus.The 
temperature range at which drug melt was noted down. 
Determination of Angle of repose andbulk density 
Angle of repose (θ) 
The angle of repose was determined by using fixed funnel 
method. The physical mixtures of drug with different 
excipients were prepared and the accurately weighed drug 
powder or its physical mixture was taken in a funnel. The 
height of the funnel was adjusted in such a way that the tip of 
the funnel just touches the apex of the heap of the drug 
powder. The powder was allowed to flow through the funnel 
freely onto surface. The angle of repose was calculated using 
the following equation. 
Tan θ= h/r 
θ= tan-1 (h/r) 
Where, θ is the angle of repose, h is the height, r is the radius. 
Bulk density 
Both loose bulk density (LBD) and tapped bulk density (TBD) 
were determined. Accurately weighed amount of granules 
taken in a 50 ml capacity measuring cylinder was tapped for 
100 times on a plane hard wooden surface and estimated the 
LBD and TBD, calculated by using following formulas. 
LBD = Powder weight/volume of the packing 
TBD = Powder weight /tapped volume of the packing 
Determination of partition coefficient  
10 mg drug was added in 50 ml of n-Octanol (pre saturated 
with water) and it was shaked and then 50 ml of distilled 
water (pre saturated with n- Octanol ) was added and was 
shaked the mixture by mechanical shaker for 24 hours. After 
24 hour both phases are separated. Absorbance was taken of 
both the phases and calculated the concentration in each 
phases18 [18]. 
Partition Coefficient = Drug concentration in 
Octanol/Drug concentration in water 
pH determination  
This was done by shaking a 1%w/v dispersion of the sample 
in water for 5min and the pH determination using a digital 
pH meter19. 
 
Drug-excipient compatibility studyby FT-IR 
Spectroscopy  
Infra- red spectrum is an important record which gives 
sufficient information about the structure of a compound.  
This technique provides a spectrum containing a large 
number of absorption band from which a wealth of 
information can be derived about the structure of an organic 
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compound. The region from 400-4000 cm-1 called infra-red 
region. Approx 5 to 10mg of drug was used as ATR 
techniques, using FT-IR spectrophotometer (Bruker, USA). 
Determination of λmax and calibration curve of drug 
Accurately weighed 10 mg of drug was dissolved in 10 ml of 
0.1 N HClsolution in 10 ml of volumetric flask. The resulted 
solution 1000µg/ml and from this solution 1 ml pipette out 
and transfer into 10 ml volumetric flask and volume make up 
with 0.1 N HCl solution, prepare suitable dilution to make it 
to a concentration range of 5-25μg/ml. The spectrum of this 
solution was run in 200-400 nm range in U.V. 
spectrophotometer (SHIMADZU UV-1800). 
RESULTS AND DISCUSSIONS 
Solubility of pralidoxime was freely soluble in 0.1 N HCl, 
methanol, soluble in water, 0.1 N NaOH, slightly soluble in 
phosphate buffer pH 6.8, ethanol. The melting point of 
pralidoximewas 212-223°C which is same as documented 
(215-225°C) and the results of true density, bulk density, 
angle of repose, pH and partition coefficient was calculated 
and the results are given in Table 1.λmax of pralidoxime was 
found to be 294 nm by using U.V. spectrophotometer 
(SHIMADZU UV-1800)in linearity range 5-25µg/ml Figure1& 
2. The FTIR spectrum of pure drug, ethyl cellulose, HPMC and 
physical mixture were recorded on ATR techniques, using 
FT-IR spectrophotometer (Bruker, USA).After observing the 
spectra, it could be concluded that the peak of all the 
characteristic functional groups of pralidoxime chlorideare 
intact in pure drug (pralidoxime chloride) and physical 
mixtures correspondingly. As there was no shifting, deleting 
and broadening of the peak observed in the spectrum, it was 
concluded that no chemical interactions occurred Figure 3.  
 
Table 1: Physicochemical properties of Pralidoxime chloride 
Parameters  Results  
Description 
 
Pralidoxime chloride occurs as an odorless, white, 
nonhygroscopic, crystalline powder 
pH 3.6 ± 0.27 
True density (gm/cc) 1.62 ± 0.42 
Bulk density (gm/cc) 0.64 ± 0.57 
Angle of repose (θ) 28.16 ± 1.15 
Partition Coefficient 0.87 ± 0.53 
 
 
Figure 1: λ max of pralidoxime chloride 
 
Figure 2: Calibration curve of pralidoxime chloride in 0.1 N HCl at 294nm 
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Figure 3: FTIR Spectra of Pralidoxime chloride (A), Ethyl cellulose (B), HPMC (C), Pralidoxime chloride+ EC+HPMC (D) 
Sharma et al                                                                                                       Journal of Drug Delivery & Therapeutics. 2019; 9(4-s):338-342 
ISSN: 2250-1177                                                                                  [342]                                                                                 CODEN (USA): JDDTAO 
CONCLUSION 
In the present work, the preformulation study of Pralidoxime 
drug was done. Preformulation studies have a significant 
part to play in anticipating formulation problems and 
identifying a logical path in both liquid and solid dosage form 
technology. Preformulation study gives brief idea about the 
identification (physical appearance, solubility studies, 
melting point, U Vand IR spectrophotometer spectra, 
estimation of drugs).This study shows a satisfactory result 
for all characterization and on the basis of this study we 
concluded that the drug was suitable for choice of 
formulation.  
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